無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

生物兵器防衛の世界市場:製品、地域別の成長率、動向および予測(2018年〜2023年)

Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 659347
出版日 ページ情報 英文 107 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
生物兵器防衛の世界市場:製品、地域別の成長率、動向および予測(2018年〜2023年) Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年06月10日 ページ情報: 英文 107 Pages
概要

世界の生物兵器防衛市場は、2018年から2023年の予測期間中に、6.5%のCAGRで成長すると予測されています。生物テロリズムは人類にとって有害な生物剤の使用方法です。生物兵器防衛には、生物剤から保護するための医療措置が含まれます。ナノテクノロジー、データベース管理システム、高度な検出器ハードウェア、法医学部門の病原体検出用遺伝子チップなど、技術的進歩が市場成長を促進する主な要因となっています。また、ワクチン生産の増加、法医学の強化、迅速な診断手順と検出技術も市場の成長を促進すると期待されています。さらに最近のニパ、エボラ、ジカウイルスの発生により、R&D資金が増加しています。先進国の地方政府による生物兵器防衛に対する投資の増加は、予測期間にわたって市場の成長を促進すると予想されています。

当レポートでは、世界の生物兵器防衛市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場の概要

  • 現在の市場シナリオ
  • パイプライン分析
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争
  • 規制シナリオ

第6章 成長要因、阻害要因、機会と挑戦分析(DROC)

  • 市場の成長要因
    • 有益な政府のイニシアチブ
    • 先進国における地方政府の投資増加
    • 急速な技術の進歩
  • 市場の阻害要因
    • 発展途上国および途上国における低い市場浸透率
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 製品別
    • 炭疽菌
    • ボツリヌス症
    • 天然痘
    • 細胞核
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Alnylam Pharmaceuticals Inc.
  • Bavarian Nordic
  • Cleveland BioLabs
  • DynPort Vaccine Company LLC
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • Ichor Medical Systems
  • Ology Bioscience
  • PharmAthene Inc.
  • SIGA Technologies

第10章 市場の将来展望

目次
Product Code: 61707

The global biodefense market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. Bioterrorism is the use of biological agents that are harmful for mankind. Biodefense includes medical measures to protect from biological agents. Key factors driving the market growth are rise in technological advancement, such as nanotechnology, database management systems, advanced detector hardware, and gene chips for pathogen detection in the forensic department. Also, the rise in the production of vaccines, enhanced forensics, and quick diagnostic procedures and detection techniques are the factors expected to drive the market growth. Additionally, due to the recent outbreak of Nipah, Ebola, and Zika viruses governments are increasing R&D funding. Increasing investments by regional governments of developed countries for biodefense are also expected to enhance the market growth over the forecast period.

Favorable Government Initiatives

Governments spend huge sums of money every year for the R&D of vaccines in order stay prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense sector have huge opportunities to expand due to governments' drive to be prepare for any kind of bioterrorism. For instance, in 2004, the US congress passed the Project Bioshield act, calling for USD 5 billion investment for purchasing vaccines which can be used in the event of a bioterrorist attack. This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. Such government initiatives are expected to propel the growth of the biodefense market.

Other factors driving this market are rapid technological advancements and increasing investments by regional governments in developed countries.

Low Market Penetration in Developing and Underdeveloped Countries

The growth of biodefense market may be hampered by the low market penetration in the developing and underdeveloped countries. Limited government interventions and funding for biodefense materials are some of the major reasons restraining the growth of the market. Developed countries have more resources to be prepared for a bio war when compared to developing countries.

North America to Dominate the Market

North America dominated the global biodefense market in 2017, which can be attributed to the increase in government funding to generate and stockpile sufficient vaccines to be used against anthrax through various initiative, such as BioShield act, Biomedical Advanced Research and Development Authority (BARDA), and Joint Program Executive Office for Chemical & Biological Defense. For instance, the US Department of Health and Human Services announced it plans to spend more than USD 25 million on an anthrax antitoxin, as a part of an emergency preparedness plan in 2018. In May 2018, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that USD 25 million was granted to advance the development and manufacture of a vaccine against the Nipah virus (NiV) to major market players, like Profectus BioSciences Inc. and Emergent BioSolutions Inc. The above mentioned initiatives by government are expected to boost the growth of the market in the region.

Key Developments in the Market:

  • February 2018 - Bavarian Nordic A/S announced positive results from a Phase 3 pivotal study of its investigational and non-replicating smallpox vaccine, IMVAMUNE
  • March 2017 - PharmAthene Inc. a biodefense company developing medical countermeasures against anthrax, announced that it has established a record date and meeting date for a special meeting of stockholders to vote upon, among other things, the proposal to adopt the agreement and plan of merger and reorganization involving PharmAthene and Altimmune Inc.
  • Major Players: ALNYLAM PHARMACEUTICALS INC., BAVARIAN NORDIC, CLEVELAND BIOLABS, DYNPORT VACCINE COMPANY LLC, ELUSYS THERAPEUTICS INC., EMERGENT BIOSOLUTIONS INC., ICHOR MEDICAL SYSTEMS, OLOGY BIOSCIENCE, PHARMATHENE INC., AND SIGA TECHNOLOGIES INDUSTRIES LTD, amongst others.

Reasons to Purchase this Report:

  • Current and future global biodefense market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter's five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the report:

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1. Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Pipeline Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining Power of Suppliers
    • 5.3.2. Bargaining Power of Consumers
    • 5.3.3. Threat of New Entrants
    • 5.3.4. Threat of Substitute Product and Services
    • 5.3.5. Competitive Rivalry within the Industry
  • 5.4. Regulatory Scenario

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1. Market Drivers
    • 6.1.1. Favorable Government Initiatives
    • 6.1.2. Increasing Investments by the Regional Governments in the Developed Countries
    • 6.1.3. Rapid Technological Advancements
  • 6.2. Market Restraints
    • 6.2.1. Low Market Penetration in Developing and Underdeveloped Countries
  • 6.3. Opportunities
  • 6.4. Key Challenges

7. Market Segmentation

  • 7.1. By Product
    • 7.1.1. Anthrax
    • 7.1.2. Botulism
    • 7.1.3. Smallpox
    • 7.1.4. Nuclear
    • 7.1.5. Others
  • 7.2. By Geography
    • 7.2.1. North America
      • 7.2.1.1. United States
      • 7.2.1.2. Canada
      • 7.2.1.3. Mexico
    • 7.2.2. Europe
      • 7.2.2.1. France
      • 7.2.2.2. Germany
      • 7.2.2.3. United Kingdom
      • 7.2.2.4. Italy
      • 7.2.2.5. Spain
      • 7.2.2.6. Rest Of Europe
    • 7.2.3. Asia-Pacific
      • 7.2.3.1. China
      • 7.2.3.2. Japan
      • 7.2.3.3. India
      • 7.2.3.4. Australia & New Zealand
      • 7.2.3.5. South Korea
      • 7.2.3.6. Rest of Asia-Pacific
    • 7.2.4. Middle East & Africa
      • 7.2.4.1. GCC
      • 7.2.4.2. South Africa
      • 7.2.4.3. Rest of the Middle East & Africa
    • 7.2.5. South America
      • 7.2.5.1. Brazil
      • 7.2.5.2. Argentina
      • 7.2.5.3. Rest of South America

8. Competitive Landscape

  • 8.1. Mergers and Acquisition Analysis
  • 8.2. Agreements, Collaborations, and Partnerships
  • 8.3. New Products Launches

9. Key Players

  • 9.1. Alnylam Pharmaceuticals Inc.
  • 9.2. Bavarian Nordic
  • 9.3. Cleveland BioLabs
  • 9.4. DynPort Vaccine Company LLC
  • 9.5. Elusys Therapeutics Inc.
  • 9.6. Emergent BioSolutions Inc.
  • 9.7. Ichor Medical Systems
  • 9.8. Ology Bioscience
  • 9.9. PharmAthene Inc.
  • 9.10. SIGA Technologies

List not Exhaustive

10. Future of the Market

Back to Top